- Home
- CLRO vs KALA Comparison
CLRO vs KALA Comparison
Compare CLRO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLRO | KALA |
|---|---|---|
| Founded | 1983 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 13.3M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLRO | KALA |
|---|---|---|
| Price | $5.03 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | ★ 1.6M | 274.5K |
| Earning Date | 05-18-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $2.71 | $0.07 |
| 52 Week High | $16.50 | $20.58 |
Technical Indicators
Market Signals| Indicator | CLRO | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 28.73 |
| Support Level | $4.44 | $0.54 |
| Resistance Level | $5.40 | $0.72 |
| Average True Range (ATR) | 0.42 | 0.11 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 17.40 | 7.71 |
Price Performance
Historical ComparisonAbout CLRO ClearOne Inc. (DE)
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.
About KALA KALA BIO Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.